Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin
BackgroundVisfatin, adropin, and adiponectin are involved in many changes associated with obesity and metabolic disorders, and may be related to metabolic syndrome and cardiovascular disease. The selection of visfatin, adropin, and adiponectin as biomarkers is based on their significant roles in met...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1527567/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206777316114432 |
|---|---|
| author | Anna Maria Cybulska Daria Schneider-Matyka Ireneusz Walaszek Mariusz Panczyk Dorota Ćwiek Anna Lubkowska Elżbieta Grochans Kamila Rachubińska Katarzyna Malewicz Mariusz Chabowski Mariusz Chabowski |
| author_facet | Anna Maria Cybulska Daria Schneider-Matyka Ireneusz Walaszek Mariusz Panczyk Dorota Ćwiek Anna Lubkowska Elżbieta Grochans Kamila Rachubińska Katarzyna Malewicz Mariusz Chabowski Mariusz Chabowski |
| author_sort | Anna Maria Cybulska |
| collection | DOAJ |
| description | BackgroundVisfatin, adropin, and adiponectin are involved in many changes associated with obesity and metabolic disorders, and may be related to metabolic syndrome and cardiovascular disease. The selection of visfatin, adropin, and adiponectin as biomarkers is based on their significant roles in metabolic regulation and inflammation, which are critical factors in cardiometabolic risk. Visfatin is known for its pro-inflammatory properties and its ability to modulate insulin resistance. Adropin is involved in energy homeostasis and metabolic health, while adiponectin has anti-inflammatory and insulin-sensitizing effects. During the perimenopausal period, the risk of obesity, and consequently cardiometabolic diseases increases. Therefore, the aim of this study was to assess the relationship between cardiometabolic parameters and circulating levels of visfatin, adropin, and adiponectin in perimenopausal women with regard to their obesity status.Materials and methodsThis study of 168 perimenopausal women utilized a cross-sectional design with non-random sampling. It involved the use of questionnaires, as well as anthropometric and blood pressure measurements. Blood samples were collected to determine the levels of visfatin, adropin, and adiponectin. Statistical analyses, including correlation coefficients, were performed to evaluate the relationship between these biomarkers and cardiometabolic risk factors, such as insulin resistance, lipid profiles, and inflammatory markers.ResultsIn our study, visceral adiposity index and lipid accumulation product negatively correlated with adiponectin levels. Preliminary multivariate linear regression analysis revealed a positive correlation between circulating visfatin and IL-6 levels. Circulating adropin negatively correlated with HbA1C, fasting blood glucose, and insulin. Adiponectin negatively correlated with HbA1C, fasting blood glucose, insulin, and triglycerides. Furthermore, circulating adiponectin positively correlated with HDL, and negatively with HOMA-IR.ConclusionsAdiponectin is a promising biomarker for predicting cardiometabolic risk in postmenopausal women. |
| format | Article |
| id | doaj-art-2e3b20a7a6604f9d975f2a7c2b702004 |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-2e3b20a7a6604f9d975f2a7c2b7020042025-02-07T05:10:29ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-02-011610.3389/fendo.2025.15275671527567Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectinAnna Maria Cybulska0Daria Schneider-Matyka1Ireneusz Walaszek2Mariusz Panczyk3Dorota Ćwiek4Anna Lubkowska5Elżbieta Grochans6Kamila Rachubińska7Katarzyna Malewicz8Mariusz Chabowski9Mariusz Chabowski10Department of Nursing, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Nursing, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Nursing, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, PolandDepartment of Obstetrics and Pathology of Pregnancy, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Functional Diagnostics and Physical Medicine, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Nursing, Pomeranian Medical University in Szczecin, Szczecin, PolandDepartment of Nursing, Pomeranian Medical University in Szczecin, Szczecin, PolandGeriatrics and Long-Term Care Department, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, Wroclaw, PolandDepartment of Surgery, 4th Military Clinical Hospital, Wroclaw, PolandDepartment of Clinical Surgical Sciences, Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, PolandBackgroundVisfatin, adropin, and adiponectin are involved in many changes associated with obesity and metabolic disorders, and may be related to metabolic syndrome and cardiovascular disease. The selection of visfatin, adropin, and adiponectin as biomarkers is based on their significant roles in metabolic regulation and inflammation, which are critical factors in cardiometabolic risk. Visfatin is known for its pro-inflammatory properties and its ability to modulate insulin resistance. Adropin is involved in energy homeostasis and metabolic health, while adiponectin has anti-inflammatory and insulin-sensitizing effects. During the perimenopausal period, the risk of obesity, and consequently cardiometabolic diseases increases. Therefore, the aim of this study was to assess the relationship between cardiometabolic parameters and circulating levels of visfatin, adropin, and adiponectin in perimenopausal women with regard to their obesity status.Materials and methodsThis study of 168 perimenopausal women utilized a cross-sectional design with non-random sampling. It involved the use of questionnaires, as well as anthropometric and blood pressure measurements. Blood samples were collected to determine the levels of visfatin, adropin, and adiponectin. Statistical analyses, including correlation coefficients, were performed to evaluate the relationship between these biomarkers and cardiometabolic risk factors, such as insulin resistance, lipid profiles, and inflammatory markers.ResultsIn our study, visceral adiposity index and lipid accumulation product negatively correlated with adiponectin levels. Preliminary multivariate linear regression analysis revealed a positive correlation between circulating visfatin and IL-6 levels. Circulating adropin negatively correlated with HbA1C, fasting blood glucose, and insulin. Adiponectin negatively correlated with HbA1C, fasting blood glucose, insulin, and triglycerides. Furthermore, circulating adiponectin positively correlated with HDL, and negatively with HOMA-IR.ConclusionsAdiponectin is a promising biomarker for predicting cardiometabolic risk in postmenopausal women.https://www.frontiersin.org/articles/10.3389/fendo.2025.1527567/fulladiponectinadropinBMImenopausal womenobesityvisfatin |
| spellingShingle | Anna Maria Cybulska Daria Schneider-Matyka Ireneusz Walaszek Mariusz Panczyk Dorota Ćwiek Anna Lubkowska Elżbieta Grochans Kamila Rachubińska Katarzyna Malewicz Mariusz Chabowski Mariusz Chabowski Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin Frontiers in Endocrinology adiponectin adropin BMI menopausal women obesity visfatin |
| title | Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin |
| title_full | Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin |
| title_fullStr | Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin |
| title_full_unstemmed | Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin |
| title_short | Predictive biomarkers for cardiometabolic risk in postmenopausal women: insights into visfatin, adropin, and adiponectin |
| title_sort | predictive biomarkers for cardiometabolic risk in postmenopausal women insights into visfatin adropin and adiponectin |
| topic | adiponectin adropin BMI menopausal women obesity visfatin |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2025.1527567/full |
| work_keys_str_mv | AT annamariacybulska predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT dariaschneidermatyka predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT ireneuszwalaszek predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT mariuszpanczyk predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT dorotacwiek predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT annalubkowska predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT elzbietagrochans predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT kamilarachubinska predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT katarzynamalewicz predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT mariuszchabowski predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin AT mariuszchabowski predictivebiomarkersforcardiometabolicriskinpostmenopausalwomeninsightsintovisfatinadropinandadiponectin |